The Clinical Significance of Cytokines and Soluble Forms of Membrane-Derived Activation Antigens in the Serum of Patients with Hodgkin's Disease

References

• Tubiana M., Henry-Amar M., Messing B., Henry J., Abbatucci J., Burgers M., Hayat M., Somers R., Laugier A., Carde P. A multivariate analysis of prognostic factors in early stage Hodgkin's disease. International Journal of Radiation Oncology Biology and Physics 1985; 11: 23–9
   PubMed Web of Science ®Google Scholar
• Lo Uffler M., Pfreundschuh M., Hasenclever D., Hiller E., Gerhartz H., Wilmanns W., Rohloff R., Rühl U., Kühn G., Fuchs R., Kirchner H., Tiechmann J., Schoppe W., Petsch S., Willhelmy W., Worst P., Pflüger K.-H., Hecht T., Battels H., Gassmann W., Krüger G., Schmitz G., Oertel W., Diehl V. Prognostic risk factors in advanced Hodgkin's lymphoma. Blut 1988; 56: 949–55
   Google Scholar
• Friedman S., Henry-Amar M., Cosset J. M., Carde P., Hayat M., Dupouy N., Tubiana M. Evolution of erythrocyte sedimentation rate as predictor of early relapse in post-therapy early-stage Hodgkin's disease. Journal of Clinical Oncology 1988; 6: 596–601
   PubMed Web of Science ®Google Scholar
• Gruss H. J., Brach M. A., Mertelsmann R., Herrmann F. Expression of cytokine and cytokine receptor genes in Hodgkin's disease derived cell lines. Proceedings of the Second International Symposium on Hodgkin's disease, Cologne, 1991
   Google Scholar
• Hsu P. L., Hsu S. M. Production of tumor necrosis factor-alpha and lymphotoxin by cells of Hodgkin's neoplastic cell lines HDLM-1 and KM-H2. American Journal of Pathology 1990; 135: 735–41
   Web of Science ®Google Scholar
• Kretschmer C., Jones D. B., Morrison K., Schluter C., Feist W., Ulmer A. J., Arnold J., Diamantstein T., Flad H. D., Stein H. Tumor necrosis factor alpha and lymphotoxim production in Hodgkin's disease. American Journal of Pathology 1990; 137: 341–51
   PubMed Web of Science ®Google Scholar
• Jücker M., Abts A., Schindler R., Merz H., Günther A., von Kalle C., Schaadt M., Diamantstein T., Feller A. G., Krüger G. R. F., Diehl V., Blankenstein T., Tesch H. Expression of interleukin-6 and interleukin-6 receptor in Hodgkin's disease. Blood 1991; 11: 2413–8
   Google Scholar
• Gause A., Scholz R., Klein S., Jung W., Diehl V., Tesch H., Pfreundschuh M. Increased levels of circulating interleukin-6 in patients with Hodgkin's disease. Haematological Oncology 1991; 9: 307–13
   PubMed Web of Science ®Google Scholar
• Sheibani K., Winberg C. D., Veld S., Blayney D. W., Rappoport H. Distribution of lymphocytes with interleukin-2 receptors (Tac antigens) in reactive lymphoproliferative processes, Hodgkin's disease, and non-Hodgkin's lymphomas: an immunohistologic study of 3000 cases. American Journal of Pathology 1987; 127: 27–37
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M., Pohl C., Berenbeck G., Schroeder J., Jung W., Schmits R., Tschiersch A., Diehl V., Gause A. Detection of a soluble form of the CD30 antigen in the sera of patients with lymphoma, adult T-cell leukemia and infectious mononucleosis. International Journal of Cancer 1990; 45: 869–74
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M., Löffler M., Rühl U., Hiller E., Gerhartz H., Wilmanns W., Kirchner H., Schoppe W., Petsch S., Bartels H., Pflüger K.-H., Teichmann J., Fuchs R., Kiihn G., Oertel W., Mertelsmann R., Dölken G., Schalk K.-P., Worst P., Wilhelmy M., Gassmann W., Loos U., Hinterberger R., Theml H., Wagner T., Samandari S., Schäfgen W., Preiss J., Schmitz N., Mende W., Mödder B., Schick H. J., Diehl V. Therapy of Hodgkin's lymphomas-Results of the German Hodgkin's Study Group. Onkologie 1988; 11: 48–52
   PubMedGoogle Scholar
• Pfreundschuh M., Schoppe W. D., Fuchs R., Pflueger K.-H., Loeffler M., Diehl V. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) for Hodgkin's lymphoma refractory to COPP and ABVD. A multicenter trial of the German Hodgkin Study Group. Cancer Treatment Reports 1987; 71: 1203–7
   PubMedGoogle Scholar
• Gause A., Roschansky V., Tschiersch A., Smith K., Hasenclever D., Schmits R., Diehl V., Pfreundschuh M. Low serum interleukin-2 receptor levels correlate with a good prognosis in patients with Hodgkin's lymphoma. Annals of Oncology 1991; 2(suppl. 2): 43–7
   PubMed Web of Science ®Google Scholar
• Gause A., Verpoort K., Roschansky V., Tschiersch A., Hasenclver D., Schmits R., Diehl V., Brosteanu O., Pfreundschuh M. The clinical significance of serum CD8 antigen levels in adult patients with Hodgkin's disease. Annals of Oncology 1991; 2: 579–83
   PubMed Web of Science ®Google Scholar
• Gause A., Keymis S., Scholz R., Schobert I., Jung W., Diehl V., Pohl C., Pfreundschuh M. Increased levels of circulating cytokines in patients with untreated Hodgkin's disease. Lymphokine and Cytokine Research 1992; 11: 109–13
   PubMedGoogle Scholar
• Ayala A., Wang P., Ba Z. F., Perrin M. M., Ertel W., Chaudry I. H. Differential alteration in plasma IL-6 and TNF levels after trauma and hemorrhage. American Journal of Physiology 1991; 260: 167–71
   PubMed Web of Science ®Google Scholar
• Sheron N., Lau J. N., Hofmann J., Williams R., Alexander G. J. Dose-dependent increase in plasma interleukin-6 after recombinant tumour necrosis factor infusion in humans. Clinical and Experimental Immunology 1990; 82: 427–8
   PubMed Web of Science ®Google Scholar
• Schindler R., Mancilla J., Endres S., Ghorbani R., Clark S. C., Dinarello C. A. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1 and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 1990; 75: 40–7
   PubMed Web of Science ®Google Scholar
• Poppema S. The nature of the lymphocytes surrounding Reed-Sternberg cells in nodular lymphocyte predominance and in other types of Hodgkin's disease. American Journal of Pathology 1989; 135: 351–7
   PubMed Web of Science ®Google Scholar
• Schwonzen M., Schuh A., Pfreundschuh M., Wickramanayake D., Diehl V. Detection of interleukin-3 as a cytoplasmatic antigen in Hodgkin's disease derived cell lines. Proceedings of the Second International Symposium on Hodgkin's Disease, Cologne, 1991, 10
   Google Scholar
• Ernst T. J., Richie A. R., Stopak K. S., Griffin J. D. Human monocytes produce IL-3 in response to stimulation with the calcium ionophore A 23187. Blood 1989; 74(Supplement)16a
   Google Scholar
• Horii Y., Muraguchi A., Suematsu S., Matsuda T., Yoshizaki K., Hirano T., Kishimoto T. Regulation of BSF-2/IL-6 production by human mononuclear cells: macrophage dependent synthesis of BSF-2/IL-6 by T cells. Journal of Immunology 1988; 141: 1529–34
   PubMed Web of Science ®Google Scholar
• Griffin J. D., Cannistra S. A., Sullivan R., Demtri G. D., Ernst T. J., Kanakury N. The biology of GM-CSF: regulation of production and interaction with its receptor. International Journal of Cell Cloning 1990; 8(Supplement 1)35–45
   PubMedGoogle Scholar
• Guba S. C., Stella G., Turka L. A., June C. H., Thompson C. B., Emerson S. G. Regulation of interleukin-3 gene induction in normal human T cells. Journal of Clinical Investigation 1989; 84: 1701–5
   PubMed Web of Science ®Google Scholar
• Hsu S. M., Hsu P. L. Lack of effect of colony-stimulating factors, interleukins, interferons, and tumor necrosis factor on the growth and differentiation of cultured Reed-Sternberg cells. Comparison with effect of phorbol ester and retinoic acid. American Journal of Pathology 1990; 136: 181–5
   PubMed Web of Science ®Google Scholar
• Grimfors G., Holm G., Mellstedt H., Schnell P. O., Tullgren O., Bjorkholm M. Increased blood clearance rate of indium-Ill oxine-labeled CD4+ blood cells in untreated patients with Hodgkin's disease. Blood 1990; 583–9
   PubMed Web of Science ®Google Scholar
• Rubin L. A., Kurman C. C., Fritz M E., Biddison W. E., Boutin B., Yarchoan R., Nelson D. L. Soluble interleukin-2 receptors are released from activated lymphoid cells in vitro. Journal of Immunology 1985; 135: 3172–7
   PubMed Web of Science ®Google Scholar
• Tomkinson B., Brown M. C., Ip S. H., et al. Soluble CD8 during T cell activation. Journal of Immunology 1989; 142: 2230–5
   PubMed Web of Science ®Google Scholar
• Hillinger S. M., Herzig G. P. Impaired cell-mediated immunity in Hodgkin's disease mediated by suppressor lymphocytes and monocytes. Journal of Clinical Investigation 1978; 61: 1620–7
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M., Mommertz E., Meissner M., Feller A. C., Hassa R., Krueger G. R. F., Diehl V. Hodgkin- and Reed-Sternberg cell associated monoclonal antibodies HRS-1 and HRS-2 react with activated cells of lymphoid and monocytoid origin. Anticancer Research 1988; 8: 217–24
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M., Carde P., da Costa L., Manil L., Lumbroso J. D., Caillou B., Boudet F., Ricard M., Hayat M., Parmentier C., Saccavini J.-C. In vivo imaging of Hodgkin's lymphomas with monoclonal antibodies. Onkologie 1989; 12(Suppl. 1)30–2
   PubMedGoogle Scholar
• Carde P., daCosta L., Manil L., Pfreundschuh M., Lumbroso J. D., Saccavini J. C., Caillou B., Ricard M., Boudet F., Hayat M., Diehl V., Parmentier P. Immunoscintigraphy of Hodgkin's disease: in vivo use of radiolabelled monoclonal antibodies derived from Hodgkin cell lines. European Journal of Cancer 1990; 26: 474–9
   PubMed Web of Science ®Google Scholar
• Slivnick D. J., Ellis T. M., Nawrocki J. F., Fisher R. I. The impact of Hodgkin's disease on the immune system. Seminars in. Oncology 1990; 17: 673–82
   Web of Science ®Google Scholar